HOYA's New Lens Halts Myopia, Aims to Corner a Growing Global Market

MISSISSAUGA, ON – July 30, 2026

In a move that sends ripples through the multi-billion-dollar vision care industry, HOYA Vision Care has unleashed its most powerful weapon yet against a burgeoning global health crisis. The Canadian launch of the MiYOSMART® iQ spectacle lens is not just another product release; it's a strategic gambit built on a staggering clinical claim: the ability to halt the progression of myopia, or nearsightedness, on average in nine out of ten children over the first year of wear.

For decades, the battle against childhood myopia has been one of mitigation—slowing a seemingly inevitable decline. But HOYA is now reframing the fight as one of cessation. As myopia rates skyrocket, with projections suggesting half the world's population will be nearsighted by 2050, the stakes have never been higher. This new lens represents a calculated play for market dominance, targeting not just the symptoms of a global epidemic but the very mechanism of its progression.

A Generational Leap in Optical Engineering

The power behind MiYOSMART iQ lies in its sophisticated design, an evolution of the company's already successful D.I.M.S. (Defocus Incorporated Multiple Segments) Technology. The original MiYOSMART lenses, which have sold over 15 million units worldwide, work by creating a zone of peripheral "defocus" that signals the eye to stop elongating—the primary cause of worsening myopia. The new MiYOSMART iQ enhances this with what the company calls a "Triple Enhanced Design" (TED).

This upgraded system features a smaller central clear zone, pushing the therapeutic defocus segments closer to the child's direct line of sight. It also increases the power of the defocus signal and extends the treatment area across the lens. The goal is to continuously activate a retinal "sweet spot" that research has identified as highly responsive to the signals that regulate eye growth.

The clinical data, presented at the prestigious Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting, is what truly sets this launch apart. A randomized controlled trial of 196 children in Hong Kong showed that those wearing MiYOSMART iQ experienced, on average, no myopia progression over 12 months. More impressively, the excessive axial elongation of the eye was reduced to levels comparable to children without any refractive error.

"Beyond stopping myopia progression on average over a period of 12 months and across childhood stages, these findings demonstrate—for the first time with myopia control spectacle lenses—efficacy in children from 4 years of age with early-onset myopia," said Dr. Natalia Vlasak, HOYA Vision Care's Global Head of Medical and Scientific Affairs. This breakthrough is critical, as early-onset myopia often leads to more severe outcomes and higher long-term health risks.

A Calculated Move in a Blurry Market

The launch of MiYOSMART iQ is a masterclass in strategic market positioning. HOYA isn't replacing its original, successful D.I.M.S. lens. Instead, it is creating a powerful two-tiered portfolio. The original MiYOSMART remains a proven and accessible option, backed by eight years of clinical data. MiYOSMART iQ is now positioned as the premium, high-efficacy solution for children with aggressive, progressive, or early-onset myopia. This segmentation allows the company to capture a wider spectrum of the market, from cost-conscious parents to those demanding the most potent intervention available.

This move places direct pressure on competitors like Essilor, whose Stellest lens operates on a similar principle of peripheral defocus, and other players like ZEISS and CooperVision. While competing products have also shown significant efficacy in slowing myopia, HOYA's claim of "halting" progression on average is a powerful marketing differentiator that resonates simply and effectively with concerned parents and clinicians.

"I've seen many innovations over the years, but MiYOSMART iQ is truly exceptional," says Ryan McAdam, Managing Director of HOYA Vision Care, Canada. "With iQ, we are ushering in an era of myopia management that has the potential to change the trajectory of children's vision health in Canada and around the world." This statement underscores the company's ambition to not just compete but to set an entirely new standard of care.

The Long View: From Correction to Public Health

The strategic importance of this technology extends far beyond corporate balance sheets. Myopia is not a benign condition. High levels of nearsightedness dramatically increase the risk of sight-threatening diseases later in life, including retinal detachment, glaucoma, and myopic maculopathy. By effectively intervening in childhood, when the eye is still developing, these risks can be substantially mitigated.

While MiYOSMART iQ's 12-month data is compelling, the technology stands on the shoulders of its predecessor. The original D.I.M.S. technology is supported by a six-year clinical study—the longest of its kind for a spectacle lens—which confirmed a sustained control effect and, crucially, no "rebound effect" where myopia accelerates after treatment stops. This long-term data provides a foundation of trust and safety that will be vital for gaining widespread adoption among eye care professionals.

"At HOYA Vision Care, we imagine a world without myopia," said John Goltermann Lassen, the company's CEO. "This milestone is truly a generational leap in myopia control and represents an important step toward the vision we are committed to shaping for children around the world."

By providing a tool that can effectively stop progression in a vast majority of young patients, HOYA is shifting the paradigm from simple vision correction to proactive, long-term vision preservation. This launch in Canada serves as a key beachhead in North America for its most advanced technology, signaling a clear intent to lead the global charge against the myopia epidemic.